Objective. The efficacy of omalizumab in severe asthma has been widely demonstrated. The
main objective of this study was to evaluate the efficacy and tolerability of omalizumab in a …

Omalizumab has been shown to be an effective add-on therapy for patients with
uncontrolled severe persistent allergic asthma. There has been a steady accumulation of …

Objective. Several clinical studies have demonstrated the effectiveness of omalizumab in
patients with severe allergic asthma but the treatment period has always been relatively …

Rationale. Severe asthma is characterized by inadequate symptom control and by high rate
of inflammation despite high doses of steroids. Omalizumab, a recombinant humanized …

Abstract Background and Aims: Although the efficacy and safety of omalizumab (OMA) in
uncontrolled severe allergic asthma has been demonstrated in several randomised …

Abstract Background Randomized Controlled Trials showed that omalizumab exhibited a
good safety and tolerability profile in patients with moderate-to-severe asthma. However …

Several years ago, omalizumab became commercially available for the treatment of severe
asthma. It remains the only monoclonal antibody to be marketed for this purpose. Since then …

Controlled clinical trials have shown the recombinant humanized monoclonal anti-IgE
antibody omalizumab to improve asthma control and reduce symptom exacerbations in …

BACKGROUND: Omalizumab is a recombinant humanized anti-IgE monoclonal antibody
indicated as an add-on treatment for severe allergic asthma, inadequately controlled despite …

Aim. To evaluate the effectiveness of omalizumab in non-atopic asthma. Methods. Using
data from a multicenter registry of severe asthma, we evaluated and compared the clinical …